Peptichemio, teniposide and high-dose dexamethasone: a new active combination for relapsing and refractory multiple myeloma. A pilot study.
Twelve patients with refractory (8 pts) and relapsing (4 pts) myeloma were treated with Peptichemio. Teniposide and high-dose dexamethasone. Eight patients experienced an objective response (5 out 8 with refractory and 3 out 4 with relapsing disease) with a median duration of 10+ months. Overall toxicity was mild to moderate and chiefly haematological. Our preliminary results seem very promising and justify a larger phase II study with this regimen.
Zaniboni
A
A
IIIa Divisione Medicina Generale, Servizio di Oncologia, Fondazione Beretta, Spedali Civili, Brescia, Italy.
Simoncini
E
E
Marpicati
P
P
Montini
E
E
Rossi
G
G
Marini
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010440:Peptichemio / Q000008:administration & dosage; D013713:Teniposide / Q000008:administration & dosage
D003907:Dexamethasone; D010440:Peptichemio; D013713:Teniposide